Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 201.2A Cx
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Castrate
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 26 (19*)
Average PDX Generation Time (days +/- SEM) 44 ± 2
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen or cryopreserved tissue)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 30049486
Markers 201.2A Cx
AR N
PSA N
PSMA N
NE Y
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
201.2A Cx USP28 -1.003 0.998 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PTEN -14.129 1.117e-04 Homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx RB1 -26.469 2.150e-08 Homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ZNRF3 -0.939 1.043 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ERF -0.919 1.058 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx MBD1 -1.001 0.999 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SMAD2 -1.001 0.999 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx TP53 -0.845 1.113 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx AKT1 -0.918 1.058 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ARID4A -0.996 1.003 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CDKN1B -1.066 0.955 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PIK3CB 0.506 2.840 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SUFU -1.241 0.846 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PTEN -1.241 0.846 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CDKN2A -1.004 0.997 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx TCERG1 -0.999 1.000 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx APC -1.051 0.965 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CHD1 -1.051 0.965 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SMARCAD1 -1.010 0.993 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CUL3 -1.075 0.949 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx MYC 0.960 3.891 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CHD7 0.559 2.946 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 201.2A
Sample Site Lung
Sample source Autopsy
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide

Patient Information

Patient Number 201
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 201.2A
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
201.2A Cx CTNNB1 474 1.0 Missense variant '3/15 . 29.9 Pathogenic/likely pathogenic, other Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx AR 255 1.0 Missense variant '8/8 . 25.3 Pathogenic Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx TP53 258 1.0 Missense variant '8/11 1.22E-05 25.3 Conflicting interpretations of pathogenicity Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx ZMYM3 184 0.98 Frameshift variant '8/25 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx MUTYH 608 0.5 Missense variant '13/16 0.0007924 20.7 Conflicting interpretations of pathogenicity Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx CACNA1H 585 0.5 Missense variant '9/35 8.90E-05 5.716 Uncertain significance Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx MSH2 280 0.49 Missense variant '16/16 6.12E-05 27.7 Uncertain significance Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx ARID1A 623 0.32 Frameshift variant '3/20 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500